Cardiome Pharma says advisory committee recommends Kynapid formula

VANCOUVER - Cardiome Pharma Corp. (TSX: COM) says an advisory committee of the U.S. Food and Drug Administration is recommending approval of Kynapid, the intravenous formulation of an investigational new drug for rapid conversion of acute atrial fibrillation....More